Development
Ultralife Corporation
ULBI
$7.70
-$0.155-1.98%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 18.82% | 32.89% | 5.08% | 51.95% | 52.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.82% | 32.89% | 5.08% | 51.95% | 52.72% |
| Cost of Revenue | 12.05% | 31.14% | 4.55% | 52.71% | 59.24% |
| Gross Profit | 45.55% | 38.48% | 6.87% | 49.37% | 31.46% |
| SG&A Expenses | 6.75% | -0.69% | -0.33% | 19.03% | 29.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.45% | 24.56% | 3.98% | 43.21% | 50.04% |
| Operating Income | 464.33% | 362.17% | 108.81% | 232.10% | 24.78% |
| Income Before Tax | 626.81% | 596.61% | -13.59% | 71.62% | 57.33% |
| Income Tax Expenses | 595.56% | 708.82% | 47.01% | 26.54% | 48.57% |
| Earnings from Continuing Operations | 638.43% | 559.06% | -108.07% | 80.05% | 59.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 800.00% | -300.00% | -57.14% | 133.33% | -83.33% |
| Net Income | 656.49% | 552.34% | -105.95% | 80.19% | 59.15% |
| EBIT | 464.33% | 362.17% | 108.81% | 232.10% | 24.78% |
| EBITDA | 470.75% | 140.41% | 17.43% | 1,119.16% | 692.75% |
| EPS Basic | 653.38% | 552.68% | -105.77% | 80.23% | 59.34% |
| Normalized Basic EPS | 643.31% | 588.30% | -14.63% | 145.86% | 56.36% |
| EPS Diluted | 640.54% | 589.67% | -105.77% | 71.59% | 63.00% |
| Normalized Diluted EPS | 640.94% | 588.30% | -14.63% | 145.86% | 56.36% |
| Average Basic Shares Outstanding | 0.65% | 0.07% | 0.20% | 0.32% | 0.42% |
| Average Diluted Shares Outstanding | 1.05% | -0.03% | 0.20% | 0.32% | 0.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |